FDA
approval
· 2023-10-18
FDA Approved: ENTRESTO — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
The FDA approved a supplemental application for ENTRESTO (sacubitril and valsartan) from Novartis Pharmaceuticals Corporation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for ENTRESTO (SACUBITRIL AND VALSARTAN)